Eli Lilly to Acquire Kelonia Therapeutics in $7 Billion Cancer Immunotherapy Deal
Eli Lilly announced a deal to acquire Kelonia Therapeutics for up to $7 billion, expanding its cancer immunotherapy pipeline.
Key Points
- Eli Lilly to buy Kelonia Therapeutics for up to $7 billion
- Deal expands Lilly's cancer immunotherapy pipeline
- Transaction pending regulatory approvals
Full Details
Eli Lilly has entered into an agreement to acquire Kelonia Therapeutics for up to $7 billion, a significant move to bolster its oncology portfolio. The deal focuses on Kelonia's innovative cancer immunotherapy pipeline, which aligns with Lilly's strategic emphasis on advancing treatments for complex diseases. This acquisition underscores the pharmaceutical industry's ongoing consolidation and investment in cutting-edge biotech research. The transaction is expected to close pending regulatory approvals and customary closing conditions, potentially reshaping competitive dynamics in the immuno-oncology market.
Why It Matters
This acquisition could accelerate innovation in cancer treatments and intensify competition among major pharma companies in the immuno-oncology space.
Get stories like this delivered daily
AI-curated news, personalized to your interests. Zero noise.
Start 7-Day Free Trial →More in Global News
What we know about the Iranian ship seized by the US
The US has intercepted an Iranian ship entering the Gulf as part of its naval blockade, US President Donald Trump has said.
US singer D4vd charged with murder stemming from death of missing teenage girl
Prosecutors say the singer, real name David Anthony Burke, could face life in prison due to the nature of the case.
Ukrainian drone attack hits Russia’s Tuapse port
Plumes of black smoke were seen after Ukrainian drones targeted Russia’s Black Sea port of Tuapse.
Iranian Envoy Summoned After Revolutionary Guards Fire On Indian Ships
The ships -- Indian-flagged cargo vessels - were fired on in the Strait of Hormuz on April 18. The incident occurred due to a communication gap between the Iranian government and the local unit of the Revolutionary Guard, sources said.